image of Karla Sagramoso
  • Telehealth Visits
bch logo

Karla Sagramoso, PhD

Psychology (Child and Adolescent Psychology)
Pediatric Psychiatry & Psychology Oakland – 53rd St.
877-822-4453
image of Karla Sagramoso
image of Karla Sagramoso
bch logo

Karla Sagramoso, PhD

Psychology (Child and Adolescent Psychology)
Pediatric Psychiatry & Psychology Oakland – 53rd St.
877-822-4453
  • Telehealth Visits

On this page

About me

Karla Sagramoso is a psychologist who provides assessment and psychotherapy for children with a wide variety of developmental, behavioral and emotional issues. Seeing patients between the ages of 3 and 21, she specializes in psychological testing and works collaboratively with families, schools and other health care professionals to clarify diagnoses and create treatment plans. She has expertise in attention-deficit/hyperactivity disorder (ADHD), learning disabilities and delays, autism spectrum disorder and other conditions. Sagramoso has served as a training coordinator for psychology interns and postdoctoral trainees in UCSF’s Department of Psychiatry and Behavioral Sciences, Early Intervention Services and Center for the Vulnerable Child. In this role, she directly supervised trainees as they learned to perform various psychological assessments and psychotherapy techniques, document the process and collaborate on cases. Sagramoso earned her doctorate in clinical psychology at the California School of Professional Psychology.

Education

School

  • PHD, Alliant International University/SF Bay Campus

Care Keywords

  • Services
    • Psychology (Child and Adolescent Psychology)

Locations

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.

    The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.